Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a Study to Assess Safety, Tolerability, and Efficacy of [212Pb]Pb-DOTAM-MAM279 in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

NCT07278479 is registered in ClinicalTrials.gov with Molecular Partners AG as lead sponsor.

NCT NCT07278479
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07278479 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a Study to Assess Safety, Tolerability, and Efficacy of [212Pb]Pb-DOTAM-MAM279 in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
Lead sponsor
Molecular Partners AG
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 18, 2026
Completion date
September 30, 2032
Enrollment
138 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

extrapulmonary neuroendocrine carcinoma (ep-nec), gastroenteropancreatic nec (gep nec), large cell neuroendocrine carcinoma, large cell pulmonary neuroendocrine carcinoma of the lung (lcnec), nec of the bladder, other dll3 expressing epnec, small cell lung cancer (sclc)